REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
ROCKVILLE, Md., Aug. 27, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at the SSIEM 2024 Annual Symposium, taking place in Porto, Portugal from September 3-6, 2024.
马里兰州洛克维尔，2024年8月27日，艾伯维公司（纳斯达克股票代码：RGNX）今天宣布，将在2024年9月3日至6日于葡萄牙波尔图举行的SSIEm 2024年度学术研讨会上分享其治疗粘多糖沉积症II型（MPS II，也称为亨特氏综合征）的RGX-121项目数据。
Abstract Title: CAMPSIITE phase I/II/III: Interim clinical update of RGX-121, an investigational gene therapy for treatment of neuronopathic mucopolysaccharidosis type II (MPS II) (PO-205)
Presenter: Roberto Giugliani, M.D., Ph.D., Professor, Department of Genetics, UFRGS, Medical Genetics Service, HCPA, Porto Alegre, Brazil
Date/Time: Wednesday, September 4, 2024; 6:15 p.m. WEST (Western European Summer Time)
摘要标题：CAMPSIITE I/II/III期：RGX-121的中期临床更新，这是一项为治疗神经细胞型粘多糖沉积症II型（MPS II）的基因治疗试验（PO-205）。
介绍人：罗伯托·乔利亚尼博士，教授，遗传学系，UFRGS，匹兹堡圣保罗医院（HCPA），巴西波尔图亚雷格里港医学遗传学服务。
日期/时间：2024年9月4日（星期三）下午6:15，西欧夏季时间（WESt）。
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit .
关于regenxbio公司。
REGENXBIO是一家领先的临床阶段生物技术公司，旨在通过基因疗法的治愈潜力改善人类生活。自2009年成立以来，REGENXBIO开创了AAV Therapeutics的发展，这是一种创新的基因疗法药物类别。REGENXBIO正在推进一系列用于视网膜和罕见疾病的AAV治疗，包括ABBV-RGX-314用于治疗激素性黄斑变性和糖尿病性视网膜病变，正在与AbbVie合作开发，RGX-202用于Duchenne的治疗和RGX-121用于MPS II的治疗。REGENXBIO的AAV Therapeutic平台已经治疗了成千上万的患者，包括诺华的ZOLGENSMA，用于治疗脊髓性肌萎缩症的儿童。作为一次性治疗，AAV Therapeutic具有改变数百万人的健康保健方式的潜力。有关更多信息，请访问 。
Contacts:
联系人：
Dana Cormack
Corporate Communications
[email protected]
达纳Cormack
企业通讯
[email protected]
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
[email protected]
投资者：
Chris Brinzey
ICR Westwicke
339-970-2843
[email protected]
SOURCE REGENXBIO Inc.
来源REGENXBIO公司。